









Markets
/
Stocks
/
nasdaq-rdhl
/

Redhill Biopharma Ltd

RDHL

1.070USD

+0.040+3.88%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.56MMarket Cap

0.02P/E TTM



Redhill Biopharma Ltd

1.070

+0.040+3.88%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Redhill Biopharma Ltd

Currency: USD Updated: 2026-02-06

Key Insights

Redhill Biopharma Ltd's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 130 out of 159 in the Pharmaceuticals industry.Institutional ownership is relatively high.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Redhill Biopharma Ltd's Score

Industry at a Glance

Industry Ranking

130 / 159

Overall Ranking

538 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Redhill Biopharma Ltd Highlights

StrengthsRisks

RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.

Growing

The company is in a growing phase, with the latest annual income totaling USD 8.04M.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Overvalued

The company’s latest PE is 0.02, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 28.22K shares, decreasing 68.06% quarter-over-quarter.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Redhill Biopharma Ltd is 4.38, ranking 159 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.80M, representing a year-over-year decrease of 90.21%, while its net profit experienced a year-over-year decrease of 106.50%.

Score

Industry at a Glance

Previous score

4.38

Change



Financials

8.93

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

0.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

0.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.98

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

5.00

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Redhill Biopharma Ltd's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Redhill Biopharma Ltd is 7.44, ranking 68 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 0.02, which is 135.60% below the recent high of 0.04 and 5287.43% above the recent low of -0.99.

Score

Industry at a Glance

Previous score

7.44

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 130/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Redhill Biopharma Ltd. The Pharmaceuticals industry's average is 7.85.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Redhill Biopharma Ltd is 2.40, ranking 154 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.31 and the support level at 0.92, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.36

Change

0.04

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.067

Sell

RSI(14)

38.338

Neutral

STOCH(KDJ)(9,3,3)

13.371

Oversold

ATR(14)

0.084

Low Volatility

CCI(14)

-114.358

Sell

Williams %R

82.051

Oversold

TRIX(12,20)

-0.196

Sell

StochRSI(14)

57.507

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.086

Sell

MA10

1.185

Sell

MA20

1.244

Sell

MA50

1.206

Sell

MA100

1.368

Sell

MA200

1.566

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Gagnon Securities LLC

17.82K

GAMMA Investing LLC

4.83K

+3476.30%

Desjardins Securities Inc.

3.39K

Rhumbline Advisers Ltd. Partnership

1.77K

BofA Global Research (US)

303.00

EverSource Wealth Advisors, LLC

38.00

The Advocates

19.00

Rothschild Investment Corporation

17.00

UBS Switzerland AG

16.00

+1500.00%

Group One Trading, L.P.

11.00

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Redhill Biopharma Ltd is 1.60, ranking 149 out of 159 in the Pharmaceuticals industry. The company's beta value is 4.89. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.